ZNTL Zentalis Pharmaceuticals, Inc.
Price Chart
Executive Summary
Zentalis Pharmaceuticals announced Phase 1b MUIR trial data for azenosertib plus paclitaxel in platinum-resistant ovarian cancer (PROC), showing a 39.1% ORR and 7.3-month median PFS across all cohorts (n=46), with a 50% ORR and 9.2-month median DOR at the 250 mg intermittent dose (n=12). The data will be presented at ASCO 2026. As a pre-revenue biotech with a $264M market cap, the filing is noteworthy for pipeline progress but does not change the risk profile.
Actionable Insight
The Phase 1b MUIR data shows azenosertib + paclitaxel meaningfully improves ORR and PFS vs. historical paclitaxel monotherapy benchmarks in heavily pre-treated PROC. The 250 mg intermittent dose suggests manageable safety. With the company's core registration strategy in Cyclin E1-positive monotherapy, this combination proof-of-concept expands the total addressable market. Expect stock volatility around the ASCO presentation on June 1, but given the early-phase nature and small sample sizes, the filing alone is a moderate positive catalyst, not a transformational event.
Key Facts
- ORR of 39.1% across all four dose cohorts (n=46) in PROC patients, vs. historical paclitaxel monotherapy ORR of ~30%.
- At the 250 mg intermittent dose (n=12), ORR was 50.0% including one complete response, with a median DOR of 9.2 months.
- Median PFS of 7.3 months across all cohorts vs. historical paclitaxel monotherapy median PFS of ~4 months.
- One Grade 5 event (sepsis) previously reported in June 2024, assessed as related to azenosertib by investigator.
- Data will be presented at ASCO 2026 (June 1, 2026).
Financial Impact
No financial data in filing; clinical data supports potential expansion of azenosertib label into combination settings, which could increase peak revenue opportunity if approved.
Risk Factors
- Small Phase 1b sample (n=46) — data may not replicate in larger randomized trials.
- Grade 5 event (sepsis) attributed to azenosertib remains a safety concern.
- No financial data filed — company has significant cash burn with no approved products.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001725160-26-000045 |
| Document: asco2026datapressreleasefi.htm | 0001725160-26-000045 |
| Document: 0001725160-26-000045-index-headers.html | 0001725160-26-000045 |
| Document: 0001725160-26-000045-index.html | 0001725160-26-000045 |
| Document: 0001725160-26-000045.txt | 0001725160-26-000045 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $3.51 awaiting T+1 | awaiting T+1 | — | $3.75 (+6.84%) |
|
Jun 1, 2026
13d ago
|
Press Release
| $3.95 $3.72 | ▼ −5.82% | ▼ −5.10% | $3.75 (−5.06%) |
|
May 21, 2026
24d ago
|
Press Release
| $4.06 $3.96 | ▼ −2.46% | ▼ −3.05% | $3.75 (−7.64%) |
|
May 21, 2026
24d ago
|
8-K
| $4.06 $3.96 | ▼ −2.46% | ▼ −3.05% | $3.75 (−7.64%) |
|
May 12, 2026
4w ago
|
8-K
| $4.28 $4.28 | · 0.00% | ▲ +0.00% | $3.75 (−12.38%) |
|
May 12, 2026
4w ago
|
Press Release
| $4.28 $4.28 | · 0.00% | ▲ +0.00% | $3.75 (−12.38%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $3.99 $3.84 | ▼ −3.76% | ▼ −4.78% | $3.75 (−6.02%) |
|
Apr 17, 2026
8w ago
|
Press Release
| $4.64 $4.03 | ▼ −13.15% | ▼ −12.95% | $3.75 (−19.18%) |
|
Apr 17, 2026
8w ago
|
8-K
| $4.64 $4.03 | ▼ −13.15% | ▼ −12.95% | $3.75 (−19.18%) |
|
Apr 9, 2026
9w ago
|
8-K
| $4.42 $6.61 | ▲ +49.55% | ▲ +49.61% | $3.75 (−15.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access